OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Herzog on Novel Therapies in Ovarian Cancer

August 27th 2018

Thomas Herzog, MD, professor of obstetrics and gynecology, deputy director, University of Cincinnati Cancer Institute, discusses novel therapies in ovarian cancer.

Dr. George on Results of the Abi Race Study for Prostate Cancer

August 27th 2018

Daniel J. George, MD, professor of medicine, surgery, member, Duke Cancer Institute, discusses results of the Abi Race study for patients with metastatic castration-resistant prostate cancer.

Dr. Sparano Discusses Unmet Needs in Metastatic Breast Cancer

August 27th 2018

Joseph A. Sparano, MD, associate director for clinical research, Albert Einstein Cancer Center, Montefiore Medical Center, discusses unmet needs in metastatic breast cancer.

Dr. Dimopoulos Reflects on Ibrutinib Plus Rituximab in Waldenstrom Macroglobulinemia

August 27th 2018

Meletios Dimopoulos, MD, professor and chairman, Department of Clinical Therapeutics at the University of Athens School of Medicine, Athens, Greece, discusses the impact of the results from the iNNOVATE study of ibrutinib (Imbruvica) plus rituximab (Rituxan) in patients with Waldenström macroglobulinemia.

Dr. Naidoo on Managing Immune-Related Adverse Events in NSCLC

August 24th 2018

Jarushka Naidoo, MBBCh, assistant professor of oncology, Johns Hopkins University, discusses managing immune-related adverse events (irAEs) in patients with non–small cell lung cancer (NSCLC).

Dr. Naumann on Neoadjuvant Chemotherapy in Patients With Ovarian Cancer

August 24th 2018

R. Wendel Naumann, MD, gynecologic oncologist, Levine Cancer Institute, Carolinas HealthCare System, discusses the use of neoadjuvant chemotherapy in patients with ovarian cancer.

Dr. Levy on Biomarkers of Response to Immunotherapy

August 24th 2018

Benjamin P. Levy, MD, assistant professor of oncology, clinical director of medical oncology, Johns Hopkins Sidney Kimmel Cancer Center, Johns Hopkins Medicine, discusses biomarkers of response to immunotherapy.

Dr. Hobbs Discusses the Treatment Landscape of CML

August 24th 2018

Gabriela S. Hobbs, MD, clinical director, Leukemia Service, assistant in medicine, Massachusetts General Hospital, discusses the treatment landscape of chronic myeloid leukemia.

Dr. Bekaii-Saab Discusses Regorafenib Use in mCRC

August 24th 2018

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses regorafenib (Stivarga) use in metastatic colorectal cancer (mCRC).

Dr. Scagliotti on Immunotherapy and Precision Medicine in Lung Cancer

August 24th 2018

Giorgio Vittorio Scagliotti, MD, PhD, chief of the Medical Oncology Division at the S. Luigi Hospital, Orbassano (Torino), and head of the Department of Oncology at University of Torino, Italy, discusses immunotherapy in the context of precision medicine in lung cancer.

Dr. Powell on MSI and dMMR as Potential Biomarkers in Endometrial Cancer

August 24th 2018

Matthew Powell, MD, associate professor, Obstetrics and Gynecology, Division of Gynecologic Oncology, Washington University School of Medicine, discusses microsatellite instability and mismatch repair deficiency as potential biomarkers in endometrial cancer.

Dr. Formenti on the Role of the Immune System in Cancer Treatment

August 24th 2018

Silvia Chiara Formenti, MD, chair, Department of Radiation Oncology, Weill Cornell, associate director, Meyer Cancer Center, radiation oncologist-in-chief, NewYork-Presbyterian Hospital, discusses the role of the immune system in cancer treatment.

Dr. Youngblood on the Process of T-Cell Differentiation in Pediatric Solid Tumors

August 23rd 2018

Benjamin A. Youngblood, PhD, assistant member, Department of Immunology, St. Jude Children’s Research Hospital, discusses the process of T-cell differentiation in pediatric solid tumors.

Dr. Singal Discusses Sequencing Therapy for HCC

August 23rd 2018

Amit G. Singal, MD, associate professor, UT Southwestern Medical Center, discusses sequencing therapy for patients with hepatocellular carcinoma.

Dr. Jabbour Discusses Recent Advancements in ALL

August 23rd 2018

Elias Jabbour, MD, an associate professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center, discusses recent advances in the treatment of patients with acute lymphoblastic leukemia.

Dr. Denes Discusses Biosimilar Pricing in Oncology

August 23rd 2018

Alex E. Denes, MD, associate professor of medicine, School of Medicine, Oregon Health and Science University, discusses biosimilar pricing in oncology.

Dr. Camidge on the KEYNOTE-024 Trial in NSCLC

August 23rd 2018

D. Ross Camidge, MD, PhD, professor, Division of Medical Oncology, Joyce Zeff Chair in Lung Cancer Research, School of Medicine, Division of Medical Oncology, University of Colorado, discusses implications of the KEYNOTE-024 trial in non–small cell lung cancer (NSCLC).

Dr. Coleman on Immunotherapy in Ovarian Cancer

August 23rd 2018

Robert Coleman, MD, professor in the department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, discusses ongoing research with immunotherapy in ovarian cancer.

Dr. Tripathy on Frontline Endocrine Therapies in HR+ Breast Cancer

August 23rd 2018

Debu Tripathy, MD, professor and chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses frontline endocrine therapies for patients with hormone receptor (HR)-positive breast cancer.

Dr. Borgen on Deciding Factors of Lymph Node Dissection in Breast Cancer

August 23rd 2018

Patrick Borgen, MD, chair, Department of Surgery, director, Breast Center, Maimonides Medical Center, discusses important factors of deciding which patients with breast cancer need axillary lymph node dissection.